Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.

ABSTRACT:

Background and objectives

Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan. Accumulating evidence has demonstrated the efficacy of topiroxostat for the treatment of hyperuricemia with or without gout. However, the safety and efficacy of topiroxostat in the clinical setting remain unclear, and there is little large-scale clinical evidence. We conducted a post-marketing observational study over 54 weeks.

Patients and methods

Patients were centrally enrolled, and case report forms of 4491 patients were collected between April 2014 and March 2019 from 825 medical sites.

Results

Overall, 4329 patients were assessed for safety and 4253 patients for effectiveness. The overall incid

SUBMITTER: Ishikawa T 

PROVIDER: S-EPMC7452866 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature